Citations

Mayo Clinic

Clear

1586 citation(s) found for "Qi, Wei".

A distance-based approach for testing the mediation effect of the human microbiome
Zhang, Jie , Wei, Zhi , Chen, Jun , Wei, Zhi

Bioinformatics | January 12, 2018 | Volume: 34 | Issue: 11 | Pages: 1875-1883

10.1093/bioinformatics/bty014 | PMID 29346509 Get It

Abstract Motivation Recent studies have revealed a complex interplay between environment, the human microbiome and health and disease. Mediation analysis of the human microbiome in these complex relationships could potentially provide insights into the role of the microbiome in the etiology of disease and, more importantly, lead to novel clinical interventions by modulating the microbiome. However, due to the high dimensionality, sparsity, non-normality and phylogenetic structure of microbiome data, none of the existing methods are suitable for testing such clinically important mediation effect. Results We propose a distance-based approach for testing the mediation effect of the human microbiome. In the framework, the nonlinear relationship between the human microbiome and independent/dependent variables is captured implicitly through the use of sample-wise ecological distances, and the phylogenetic tree information is conveniently incorporated by using phylogeny-based distance metrics. Multiple distance metrics are utilized to maximize the power to detect various types of mediation effect. Simulation studies demonstrate that our method has correct Type I error control, and is robust and powerful under various mediation models. Application to a real gut microbiome dataset revealed that the association between the dietary fiber intake and body mass index was mediated by the gut microbiome. Availability and implementation An R package ‘MedTest’ is freely available at https://github.com/jchen1981/MedTest. Supplementary information Supplementary data are available at Bioinformatics online.
Three‐Dimensional Shear Wave Elastography for Differentiating Benign From Malignant Thyroid Nodules
Zhao, Chong‐Ke , Chen, Shigao , He, Ya‐Ping, Wang, Qiao , Wang, Dan , Yue, Wenwen , Zhang, Kun , Wei, Qing , Xu, Hui‐Xiong, Chen, Shi-Gao, Alizad, Azra , He, Ya‐Ping, Qu, Shen , Xu, Hui‐Xiong

Journal of Ultrasound in Medicine | January 10, 2018 | Volume: 37 | Issue: 7 | Pages: 1777-1788

10.1002/jum.14531 | PMID 29315789 Get It

ObjectivesTo prospectively evaluate the diagnostic performance of 3‐dimensional (3D) shear wave elastography (SWE) for assessing thyroid nodules.MethodsA total of 176 surgically or cytologically confirmed thyroid nodules (63 malignant and 113 benign) in 176 patients who had undergone conventional ultrasound (US), 2‐dimensional (2D) SWE, and 3D SWE examinations were included in this study. Quantitative elasticity values (mean elasticity, maximum elasticity, and standard deviation of elasticity of a large region of interest and mean elasticity of a 2‐mm region of interest) were measured on 2D and 3D SWE. Diagnostic performances of conventional US, 2D SWE, and 3D SWE were assessed. The role of 2D and 3D SWE in reducing unnecessary fine‐needle aspiration (FNA) for nodules with low suspicion was also evaluated.ResultsThe diagnostic performances in terms of the area under the receiver operating characteristic curve were 0.612 for conventional US, 0.836 for 2D SWE (P < .001 in comparison with conventional US), and 0.839 for 3D SWE (P < .001 in comparison with conventional US). The mean elasticity achieved the highest diagnostic performance in 2D SWE, whereas the standard deviation of elasticity achieved the highest performance in 3D SWE, although no significant difference was found between them (P > .05). Three‐dimensional SWE increased the specificity in comparison with 2D SWE (88.5% versus 82.3%; P = .039). For the 37 nodules with low suspicion on conventional US imaging, 2D SWE was able to avoid unnecessary FNA in 77.1% (27 of 35) of benign nodules, and 3D SWE further increased the number to 88.6% (31 of 35).ConclusionsThree‐dimensional SWE is a useful tool for predicting thyroid nodule malignancy and reducing unnecessary FNA procedures in thyroid nodules with low suspicion of malignancy.
Medial Open Transversus Abdominis Plane (MOTAP) Catheters Reduce Opioid Requirements and Improve Pain Control Following Open Liver Resection
Karanicolas, Paul J. , McHardy, Paul , Kiss, Alex , Sawyer, Jason , Behman, Ramy , Ladak, Salima , McCluskey, Stuart A. , Srinivas, Coimbatore, Katz, Joel , Coburn, Natalie G. , Law, Calvin , Wei, Alice C. , Greig, Paul D., Hallet, Julie , Clarke, Hance , Cleary, Sean, Cleary, Sean P.

Annals of Surgery | January 4, 2018 | Volume: 268 | Issue: 2 | Pages: 233-240

10.1097/sla.0000000000002657 | PMID 29300708 Get It

Objective: Conventional management of pain following open liver resection involves intravenous, patient-controlled analgesia (IV PCA) or epidural analgesia. The objective of this trial was to assess the efficacy of a regional technique called Medial Open Transversus Abdominis Plane (MOTAP) catheter analgesia compared with IV PCA. Methods: This was a blinded, randomized, controlled parallel-arm trial conducted at 2 high-volume centers. Patients undergoing liver resection through a subcostal incision were enrolled. Using a standardized technique, 2 catheters were placed after resection: one in the plane between internal oblique and transversus abdominis and the other in the posterior rectus sheath. Patients were randomized to receive ropivacaine 0.2% (ROP) or saline (NS) through both catheters for 72 hours. All patients received IV PCA with hydromorphone as part of a multimodality analgesia program. Primary outcome was opioid use over the first 48 hours. Results: One hundred fifty-three patients were included in the analysis (71 ROP, 82 NS). Patients receiving ROP used significantly less opioid than patients with NS at 48 hours (median 39.6 mg morphine-equivalent vs 49.2 mg, P = 0.033) and at 72 hours (median 50.0 vs 66.4 mg, P = 0.046). Pain scores at rest and with coughing were significantly lower at all time points in patients who received ROP (P = 0.002). Median length of hospital stay was 5 days in patients receiving ROP and 6 days in patients who received NS (P = 0.035). There was no difference between groups in complications [ROP 20 (28.2%) vs NS 26 (31.7%), P = 0.63]. Conclusion: MOTAP catheter analgesia reduces opioid requirements, pain, and length of hospital stay compared with IV PCA following open liver resection with subcostal incisions.
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, Diana , Margolis, Claire A. , Gao, Wenhua , Voss, Martin H. , Li, Wei , Martini, Dylan J. , Norton, Craig, Bossé, Dominick , Wankowicz, Stephanie A. , Cullen, Dana, Horak, Christine E., Wind‐Rotolo, Megan , Tracy, Adam , Giannakis, Marios , Hodi, F. Stephen , Drake, Charles G. , Ball, Mark W. , Hellmann, Matthew D. , Ho, Thai H. , Kaelin, William G. , Choueiri, Toni K. , Hodi, Frank Stephen , Allaf, Mohamad E , Snyder, Alexandra , Hellmann, Matthew D , Ho, Thai , Motzer, Robert J , Signoretti, Sabina , Kaelin, William G , Choueiri, Toni K , Van Allen, Eliezer M , Voss, Martin H , Motzer, Robert J.

Science | January 4, 2018 | Volume: 359 | Issue: 6377 | Pages: 801-806

10.1126/science.aan5951 | PMID 29301960 Get It

SNF'ing out antitumor immunity Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745
Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
Nepal, Chirag , O’Rourke, Colm J. , Oliveira, Douglas V.N.P. , Taranta, A , Shema, Steven , Gautam, Prson , Caldéraro, Julien , Barbour, Andrew P. , Wennerberg, Krister , Wang, Xin Wei , Lautem, Anja , Roberts, Lewis R. , Andersen, Jesper B. , Roberts, Lewis R , Andersen, Jesper B , Wei Wang, Xin , Raggi, Chiara , Gautam, Prson , Wennerberg, Krister

Hepatology | December 26, 2017 | Volume: 68 | Issue: 3 | Pages: 949-963

10.1002/hep.29764 | PMID 29278425 Get It

Intrahepatic cholangiocarcinoma remains a highly heterogeneous malignancy that has eluded effective patient stratification to date. The extent to which such heterogeneity can be influenced by individual driver mutations remains to be evaluated. Here, we analyzed genomic (whole‐exome sequencing, targeted exome sequencing) and epigenomic data from 496 patients and used the three most recurrently mutated genes to stratify patients ( IDH , KRAS , TP53 , “undetermined”). Using this molecular dissection approach, each subgroup was determined to possess unique mutational signature preferences, comutation profiles, and enriched pathways. High‐throughput drug repositioning in seven patient‐matched cell lines, chosen to reflect the genetic alterations specific for each patient group, confirmed in silico predictions of subgroup‐specific vulnerabilities linked to enriched pathways. Intriguingly, patients lacking all three mutations (“undetermined”) harbored the most extensive structural alterations, while isocitrate dehydrogenase mutant tumors displayed the most extensive DNA methylome dysregulation, consistent with previous findings. Conclusion : Stratification of intrahepatic cholangiocarcinoma patients based on occurrence of mutations in three classifier genes ( IDH , KRAS , TP53 ) revealed unique oncogenic programs (mutational, structural, epimutational) that influence pharmacologic response in drug repositioning protocols; this genome dissection approach highlights the potential of individual mutations to induce extensive molecular heterogeneity and could facilitate advancement of therapeutic response in this dismal disease. (H epatology 2018).
CNP is present in canine renal tubular cells and secreted by cultured opossum kidney cells
Nir, Amiram , Beers, K. W., Clavell, Alfredo L. , Wei, C , Heublein, D. M., Douša, Thomas P., Burnett, John C. , Heublein, Denise M.

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | December 25, 2017 | Volume: 267 | Issue: 6 | Pages: R1653-R1657

10.1152/ajpregu.1994.267.6.r1653 | PMID 7810777 Get It

C-type natriuretic peptide (CNP) is a vasoactive and antimitogenic peptide that is structurally similar but genetically distinct from atrial natriuretic peptide. While first discovered in the brain, CNP has been shown to be produced by endothelial cells and may function in a paracrine and autocrine fashion in the control of vascular tone. Recently, CNP immunoreactivity and B-type natriuretic peptide receptors (NPR-B), for which CNP is a specific ligand, have been identified in the kidney. The present study was designed to determine whether renal epithelial cells produce and secrete CNP and whether CNP immunoreactivity is present in canine kidney. Opossum kidney (OK) cells that express proximal tubular cell characteristics were incubated for 6 h in fetal calf serum-free Dulbecco's modified Eagle's medium (DMEM). CNP immunoreactivity was measured in the preincubation and 6-h conditioned media by radioimmunoassay (RIA) using a specific antibody to CNP-22. Furthermore the molecular form of this CNP-like protein was determined by reverse-phase high-performance liquid chromatography (HPLC), and intracellular localization of the CNP immunoreactivity was determined by immunohistochemical staining. CNP immunoreactivity was also determined in renal tissue from dogs subjected to saline or endothelin infusion. Six-hour incubation in DMEM resulted in accumulation of CNP immunoreactivity (baseline below detection level vs. 6 h = 117.3 +/- 8.3 pg/ml, P < 0.001). Intracellular CNP concentration determined after sonication was 1.9 +/- 0.2 micrograms/g protein, and immunohistochemical staining for CNP was markedly positive in the cytoplasm.(ABSTRACT TRUNCATED AT 250 WORDS)
C-type natriuretic peptide: a selective cardiovascular peptide
Clavell, Alfredo L. , Stingo, A. J., Wei, Chao , Heublein, Denise M., Burnett, John C.

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | December 24, 2017 | Volume: 264 | Issue: 2 | Pages: R290-R295

10.1152/ajpregu.1993.264.2.r290 | PMID 8383462 Get It

Studies were performed in three groups of anesthetized dogs to compare the structurally related peptides atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Group 1 (n = 5) and group 2 (n = 4) received intravenous infusions of CNP or ANP respectively at doses of 10 ng.kg-1.min-1 and 100 ng.kg-1.min-1. Group 3 (n = 5) received CNP intrarenally at doses of 1 ng.kg-1.min-1 and 5 ng.kg-1.min-1. Intravenous infusion of CNP resulted in a greater decrease in blood pressure when compared with ANP. This marked decrease in blood pressure observed with CNP was associated with a significantly smaller increase in guanosine 3',5'-cyclic monophosphate (cGMP). In contrast, neither intravenous nor intrarenal administration of CNP was associated with natriuresis as observed with ANP. The current study also demonstrates the presence of CNP immunoreactivity in canine plasma at low picomolar concentrations. Further characterization by gel permeation chromatography demonstrated that circulating CNP immunoreactivity corresponds to the 22-amino acid form of the peptide. In conclusion, this study demonstrates that CNP circulates in low picomolar concentrations and is potently vasoactive in vivo, suggesting a potential role in the regulation of vascular tone.
Renal localization and actions of adrenomedullin: a natriuretic peptide
Jougasaki, Michihisa , Wei, C , Aarhus, L L, Heublein, Denise M., Sandberg, S. M., Burnett, John C. , Sandberg, Sharon M.

American Journal of Physiology-Renal Physiology | December 23, 2017 | Volume: 268 | Issue: 4 | Pages: F657-F663

10.1152/ajprenal.1995.268.4.f657 | PMID 7733322 Get It

Adrenomedullin (ADM) is a newly described 52-amino acid peptide originally isolated from extracts of human pheochromocytoma and, more recently, detected in human plasma. Based on the report that ADM mRNA and immunoreactivity are present in the kidney, the current study was designed to determine the renal distribution of ADM by immunohistochemistry and the renal biological actions of ADM. In the immunohistochemical studies, the present investigation demonstrated the localization of ADM in glomeruli, cortical distal tubules, and medullary collecting duct cells of the normal canine kidney. In the in vivo studies, ADM was administered (0.25 ng.kg-1.min-1 in group I and 1, 5, and 25 ng.kg-1.min-1 in group II) intrarenally in normal mongrel dogs with the contralateral kidney receiving only saline vehicle. Intrarenal infusion of ADM resulted in a marked diuretic and natriuretic response, whereas the contralateral kidney showed no renal effects. These significant natriuresis and diuresis in the ADM kidney were associated with increases in glomerular filtration rate and fractional sodium excretion and with a decrease in distal tubular sodium reabsorption. Intrarenal infusion of ADM also caused an increase in mean arterial blood pressure and a decrease in heart rate. Plasma concentrations of atrial natriuretic peptide, renin activity, aldosterone, and guanosine 3',5'-cyclic monophosphate were not changed during the infusion of ADM. The current study demonstrates that ADM is present in renal glomerular and tubular cells and is a potent natriuretic peptide that may play an important role in the regulation of sodium excretion.
Glucose and forskolin regulate IAPP gene expression through different signal transduction pathways
Ding, Wei-Qun, Holicky, Eileen L., Ding, Wei‐Qun , Miller, Laurence J.

American Journal of Physiology-Endocrinology and Metabolism | December 22, 2017 | Volume: 281 | Issue: 5 | Pages: E938-E945

10.1152/ajpendo.2001.281.5.e938 | PMID 11595649 Get It

Molecular mechanisms for the regulation of islet amyloid polypeptide (IAPP) gene expression remain unclear. In the present study, we investigated the effects of glucose and forskolin on IAPP gene regulation in the INS-1 islet β-cell line. Both glucose and forskolin increased the level of expression of this gene, as measured by Northern blot analysis, and increased IAPP gene transcription in a time- and concentration-dependent manner, as demonstrated in a reporter gene assay. Although inhibition of protein kinase A activity with H-89 eliminated the effect of forskolin on this gene, the glucose effect was unaffected. This supported the predominant use of a protein kinase A-independent signaling pathway for glucose regulation of the IAPP gene. Electrophoretic mobility shift assay further indicated that glucose and forskolin regulated expression of this gene by targeting different elements of the promoter. Mutation of the cAMP regulatory element flanking the IAPP coding region resulted in the loss of most of the forskolin-stimulated IAPP gene promoter activity, whereas glucose-enhanced IAPP gene transcription was unaffected. These results demonstrate parallel and distinct regulatory pathways involved in glucose- and forskolin-induced IAPP gene expression in this model β-cell system.